The FDA-funded data analysis found no clear advantage of one type of hip implant over another for effectiveness and reported a potential for harm using metal-on-metal implants. The paper examines 3,139 patients enrolled in 18 comparative studies and more than 830,000 surgeries reported in national registries.
The authors found that while a single trial showed fewer revisions for ceramic-on-ceramic implants, as compared with metal-on-polyethylene implants, national registry data did not support the finding.
An article based on the analysis will be published in the Dec. 1 edition of the journal BMJ.
Related Articles on Orthopedic Implants:
Global Implant Market to Reach $46.5B by 2017
21 Spine Devices Receive FDA 510(k) Clearance in October
Hospital for Special Surgery Receives $1M Grant for Mary and Fred Trump Institute for Implant Analysis
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.